Showing results (41-50 of 80) with videos related to

Sort By:
Pageof 8
Plos One|April 13, 2011
Results of antiretroviral treatment interruption and intensification in advanced multi-drug resistant HIV infection from the OPTIMA trialMark Holodniy, Sheldon T Brown, D William Cameron, et al.
BMJ Open|May 24, 2023
Accelerating clinical development of a live attenuated vaccine against Salmonella Paratyphi A (VASP): study protocol for an observer-participant-blind randomised control trial of a novel oral vaccine using a human challenge model of Salmonella Paratyphi A infection in healthy adult volunteersNaina McCann, Katherine Emary, Nisha Singh, et al.
Lancet (London, England)|October 3, 2017
Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Salmonella Typhi: a randomised controlled, phase 2b trialCelina Jin, Malick M Gibani, Maria Moore, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 26, 2018
The Impact of Vaccination and Prior Exposure on Stool Shedding of Salmonella Typhi and Salmonella Paratyphi in 6 Controlled Human Infection StudiesMalick M Gibani, Merryn Voysey, Celina Jin, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 17, 2013
Cost-effectiveness of newer antiretroviral drugs in treatment-experienced patients with multidrug-resistant HIV diseaseAhmed M Bayoumi, Paul G Barnett, Vilija R Joyce, et al.
Trials|December 23, 2015
Oral versus intravenous antibiotic treatment for bone and joint infections (OVIVA): study protocol for a randomised controlled trialHo Kwong Li, Matthew Scarborough, Rhea Zambellas, et al.
The Journal of Infection|February 12, 2019
Novel genetically-modified chimpanzee adenovirus and MVA-vectored respiratory syncytial virus vaccine safely boosts humoral and cellular immunity in healthy older adultsChristopher A Green, Charles J Sande, Elisa Scarselli, et al.
JCI Insight|June 8, 2023
Understanding the treatment benefit of hyperimmune anti-influenza intravenous immunoglobulin (Flu-IVIG) for severe human influenzaHillary A Vanderven, Deborah N Wentworth, Win Min Han, et al.
The Lancet. HIV|January 9, 2017
Effect of immediate initiation of antiretroviral therapy on risk of severe bacterial infections in HIV-positive people with CD4 cell counts of more than 500 cells per μL: secondary outcome results from a randomised controlled trialJemma O'Connor, Michael J Vjecha, Andrew N Phillips, et al.
Plos One|March 8, 2013
The association between serum biomarkers and disease outcome in influenza A(H1N1)pdm09 virus infection: results of two international observational cohort studiesRichard T Davey, Ruth Lynfield, Dominic E Dwyer, et al.
Pageof 8